MDMA is the First Psychedelic Drug Submission Seeking FDA Approval
This marks a significant moment in the widespread acceptance of using psychedelics for therapeutic use.
Big Idea:
The Multidisciplinary Association for Psychedelic Studies (MAPS) has submitted its application to the FDA for the approval of MDMA-assisted therapy for patients with PTSD.
Why It Matters:
This marks a significant moment in psychedelic research for therapeutic use following 30 years of clinical research. The anticipation of MDMA's regulatory approval reflects a growing understanding of its therapeutic benefits, challenging long-held stigmas associated with psychedelic drugs.
Key Details:
- The application is based on two phase 3 studies demonstrating the efficacy of MDMA in reducing PTSD symptoms.
- Treated patients showed a significant drop in severity scores compared to the placebo group, with nearly half of treated patients meeting criteria for remission after the third dose.
- If the FDA approves the application, MAPS aims to work with regulators to reclassify MDMA from a Schedule 1 drug (no medical use, high risk of abuse).
What's Next:
MAPS’ MDMA application could see FDA approval by August with priority review. The organization’s goal is to explore the therapeutic potential of MDMA in areas where effective treatments are currently limited, with a particular emphasis on disorders that disproportionately affect women.
By the Numbers:
- 88% of participants in the first Phase 3 trial showed a significant reduction in PTSD symptoms.
- Nearly half of the treated patients reached remission criteria after the third MDMA dose, versus 21.4% in the placebo group.
- Durable improvements in symptom severity observed at least six months post-treatment.
Flashback:
Founded in 1986, MAPS initiated its first clinical trial involving MDMA for PTSD in 2004. The MAPS Public Benefit Organization, focused on FDA approval, was launched in 2014.
<script type="application/ld+json">
{
"@context": "https://schema.org",
"@type": "Article",
"mainEntityOfPage": {
"@type": "WebPage",
"@id": "https://www.themoney.game/stories/mdma-is-the-first-psychedelic-drug-submission-seeking-fda-approval"
},
"headline": "MDMA is the First Psychedelic Drug Submission Seeking FDA Approval",
"description": "This marks a significant moment in the widespread acceptance of using psychedelics for therapeutic use.",
"image": "",
"author": {
"@type": "Organization",
"name": "The Money Game",
"url": "https://www.themoney.game"
},
"publisher": {
"@type": "Organization",
"name": "The Money Game",
"logo": {
"@type": "ImageObject",
"url": ""
}
},
"datePublished": "2023-12-18"
}
</script>
Companies innovating in this space
Subscribe to our weekly newsletter
Browse by category
